Shares of DexCom Inc. rallied 7.22% to $77.98 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index falling 0.51% to 7,533.77 and Dow Jones ...
Wall Street still prices Abbott like a dividend stalwart, but overlooked moves suggest that framing may be costing investors ...
BTIG analyst Marie Thibault maintained a Buy rating on Dexcom on July 10 and set a price target of $80.00. The company’s shares closed yesterday at $74.96. TipRanks Welcomes a New ETF – NYSE:RANK ...
Zacks Investment Research on MSN
DXCM secures Health Canada authorization for Dexcom G7 15 day CGM
DexCom DXCM recently announced that the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System has received ...
Healthy influencers are embracing a wearable once reserved for diabetes patients to optimize their health. But experts say ...
(NASDAQ: DXCM), the global leader in glucose biosensing, announced today that Health Canada has authorized the Dexcom G7 15 ...
Smartwatches still can’t measure blood sugar on their own, but AI-powered CGMs are changing how glucose data is tracked and ...
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights: Revenue ...
DXCM's expanding CGM reach, G7 15 Day rollout and international momentum support growth, but can reimbursement and cost risks ...
Following expanded FDA approval for pediatric patients, the over-the-counter Stelo continuous glucose monitor is adding AI coaching and other app-based features.
AI may help smartwatches make glucose data more useful through better predictions, pattern detection, and personalized health ...
Continuous glucose monitors have become popular among those who need to track their glucose levels because they're painless devices. These monitors also connect to an app on your smartphone or Apple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results